XBIO financial statements and SEC filings

XBIO annual income statement

Fiscal period endRevenueOperating incomeNet incomeSEC filing
2025-12-31$2.98M-$2.83M-$2.68M10-K
2024-12-31$2.50M-$4.20M-$3.96M10-K
2023-12-31$2.54M-$4.52M-$4.13M10-K
2022-12-31$1.71M-$6.72M-$6.55M10-K
2021-12-31$1.16M-$5.75M-$5.65M10-K
2020-12-31$436.94K-$13.94M-$10.89M10-K

XBIO annual balance sheet

Fiscal period endAssetsLiabilitiesEquitySEC filing
2025-12-31$8.36M$968.02K$7.40M10-Q
2024-12-31$6.90M$894.26K$6.01M10-K
2023-12-31$10.61M$809.59K$9.80M10-K
2022-12-31$14.72M$1.07M$13.65M10-K
2021-12-31$19.82M$1.42M$18.39M10-K
2020-12-31$13.18M$963.97K$12.22M10-K

XBIO annual cash flow

Fiscal period endOperating cash flowCapital expenditureFinancing cash flowSEC filing
2025-12-31-$2.29M–$4.00M10-K
2024-12-31-$2.82M–$0.0010-K
2023-12-31-$4.11M––10-K
2022-12-31-$4.65M–$0.0010-K
2021-12-31-$4.74M–$11.45M10-K
2020-12-31-$4.27M–$5.43M10-K